Martin Daly (Roscommon-Galway, Fianna Fail)
Link to this: Individually | In context

923. To ask the Minister for Health if she will provide an update on the implementation of spinal muscular atrophy (SMA) screening in the National Newborn Bloodspot Screening Programme; if she will confirm the expected timeline for the commencement of routine SMA screening for newborns; and if she will make a statement on the matter. [60986/25]

Eoin Hayes (Dublin Bay South, Social Democrats)
Link to this: Individually | In context

938. To ask the Minister for Health her views on including spinal muscular atrophy in the national newborn screening programme; and if she will make a statement on the matter. [61040/25]

Emer Currie (Dublin West, Fine Gael)
Link to this: Individually | In context

944. To ask the Minister for Health if her Department is considering adding a test for spinal muscular atrophy to the heel prick test for newborns; and if she will make a statement on the matter. [61074/25]

Emer Currie (Dublin West, Fine Gael)
Link to this: Individually | In context

945. To ask the Minister for Health to provide an update on the engagement between her Department officials and the HSE regarding implementing a timeframe for the introduction of screening for SMA and SCID; and if she will make a statement on the matter. [61075/25]

Conor Sheehan (Limerick City, Labour)
Link to this: Individually | In context

970. To ask the Minister for Health when severe combined immunodeficiency and spinal muscular atrophy will be added to the Newborn Bloodspot Screening Programme; and if she will make a statement on the matter. [61250/25]

Richard Boyd Barrett (Dún Laoghaire, People Before Profit Alliance)
Link to this: Individually | In context

1022. To ask the Minister for Health if she will roll out the inclusion of a test for spinal muscular atrophy by November 2025, the second anniversary of the announcement that it would be added (details supplied). [61601/25]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context

I propose to take Questions Nos. 923, 938, 944, 945, 970 and 1022 together.

As Minister for Health, I am determined to support our screening programmes, which are a valuable part of our health service, enabling early treatment and care for many people, and improving the overall health of our population.

Currently, all babies (between 3 and 5 days old) are offered newborn bloodspot screening (generally known as the ‘heel prick’ test), which tests for nine rare but serious conditions that are treatable if detected early in life. The Programme for Government commits to continually reviewing the number of conditions babies are screened for.

Incremental progress continues to be made on the expansion of the National Newborn Bloodspot Screening Programme (NNBSP). In 2023, two recommendations from the National Screening Advisory Committee (NSAC) on the addition of Severe Combined Immunodeficiency (SCID) and Spinal Muscular Atrophy (SMA) to the NNBSP were approved.

In Budget 2024, an additional €1.4 million of new development funding was provided to support the SMA/SCID implementation process. Once both conditions have been fully implemented, the number of conditions screened for in Ireland will increase to 11.

In terms of the current implementation status, the HSE has advised that the equipment needed to enable the roll-out testing for SMA and SCID has been purchased, delivered and successfully installed at the newborn screening laboratory and significant progress continues with regards to the laboratory verification process. The recruitment process to hire the additional staff required to support the expansion of the NNBSP has been completed and work continues on developing screening pathways for both conditions.

In relation to concerns raised around the length of the implementation process, it should be emphasised that Ireland is not taking longer than other comparable countries to assess and implement additions to the NNBSP.

The Health Council of the Netherlands first recommended screening for SMA in 2019 and implementation was completed three years later in October 2022. In the United States of America, it took six years to fully implement SMA screening after it was added to the Recommended Uniform Screening Panel (RUSP) in 2018. In the United Kingdom, screening for SCID and SMA have been under consideration by the UK National Screening Committee since 2017 and 2018 respectively.

Nevertheless, I am acutely aware of how difficult it is for parents, families and children who have received a diagnosis of a rare disease, and how challenging daily life can be for them. This is why I remain committed to the further expansion of screening in Ireland in accordance with internationally accepted criteria and best practice.